Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO)
May 13 2021 - 5:24PM
Business Wire
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
technology, today announced the appointment of Brian C. Bock as the
Company’s Chief Financial Officer (CFO) effective immediately.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210513006058/en/
Brian C. Bock (Photo: Business Wire)
“Exicure’s proprietary SNA platform technology holds great
potential for treating unmet neurological and rare diseases. I am
pleased to be joining such a talented and dedicated team,” said Mr.
Bock, CFO of Exicure. “I look forward to providing my finance
expertise and supporting the Company’s goals and upcoming
milestones.”
Mr. Bock brings over 20 years of life science investment
banking, mergers and acquisitions and partnering experience to the
Company. Previously, he served as Managing Director, Healthcare
Investment Banking at Lincoln International, leading the firm’s
investment banking advisory engagements with early-stage life
science companies. Mr. Bock has an extensive history of working in
partnership with early to late-stage healthcare clients, public
institutional investors, and venture capital and private equity
firms. Prior to his time at Lincoln International, Mr. Bock served
as Managing Director, Healthcare Investment Banking at JMP
Securities and was a member of the Healthcare Investment Banking
team at RBC Capital Markets. Mr. Bock earned his B.S. in Finance
from Northern Arizona University.
“Brian’s expertise will be an important addition to Exicure as
we work to grow the Company’s business strategy and valuation, and
I am delighted to have him join our executive team,” said Dr. David
Giljohann, Chief Executive Officer of Exicure.
Inducement Award
The Company also announced the grant of an inducement award to
Mr. Bock. In connection with his appointment, the Compensation
Committee of the Company’s Board of Directors approved a stock
option grant to Mr. Bock as an inducement material to Mr. Bock
entering into employment with the Company, in accordance with
Nasdaq Listing Rule 5635(c)(4). The option provides for the
purchase of up to 600,000 shares of the Company’s common stock, at
an exercise price of $1.54 per share, the closing price per share
of the Company’s common stock on the date of grant. The grant vests
over four years, with 25% of the shares subject to the option
vesting on the first anniversary of Mr. Bock’s employment start
date, and the remainder vesting in a series of thirty-six
successive equal monthly installments over the following three
years, subject to Mr. Bock’s continued service to the Company
through such applicable vesting dates. The option has a ten-year
term and is subject to the terms and conditions of the stock option
agreement pursuant to which the option is granted.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on its
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN a
lipid-nanoparticle SNA–based therapeutic candidate, for the
intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s
therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2
clinical trial in patients with advanced solid tumors. Exicure is
based in Chicago, IL and in Cambridge, MA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210513006058/en/
Rebecca Peterson 617-678-5711 Rpeterson@exicuretx.com
Karen Sharma 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024